Endo Int'l (ENDP) Tops Q1 EPS by 13c; Reaffirms
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Endo Reports First-Quarter 2017 Financial Results
May 9, 2017 6:30 AM EDTDUBLIN, May 9, 2017 /PRNewswire/ --
First-quarter 2017 revenues increased 8 percent from prior year to $1,038 million First-quarter 2017 U.S. Generic Pharmaceuticals revenue increased 24 percent to $722 million First-quarter 2017 reported $0.74 diluted (GAAP) loss per share from continuing operations First-quarter 2017 adjusted diluted earnings per share (EPS) from continuing operations increased 14 percent to $1.23 First-quarter 2017 reported (GAAP) consolidated net loss of $174 million First-quarter 2017 adjusted EBITDA increased 21 percent to $478 million Company reaffirms 2017 full-year revenues, adjusted EBITDA and adjusted diluted EPS financial guidanceEndo International... More



